Navigation Links
Centrillion Biosciences Announces Next-Gen Sequencing Innovation Grant Program
Date:4/25/2013

Palo Alto, CA (PRWEB) April 25, 2013

Centrillion Biosciences, a leading genomic and bioinformatics solution provider, has announced a new grant program focused on innovation in the application of next-gen sequencing technology. The Sequencing Innovation Grant award is open to academic, clinical and industrial researchers. The Grant will be awarded to research proposals demonstrating innovative applications of next generation sequencing technology.

Grants will be awarded in the form of sample sequencing and bioinformatics analysis services for moderate sized projects. Projects involving whole genomes, exomes, targeted and transcriptome sequencing are eligible.

While the grant is open to all researchers, the initial focus will be on encouraging investigators who are new to next generation sequencing technology to embark on pilot projects that have the greatest potential to lead to significant research programs. The study areas are open but proposals to further findings that may lead to potential clinical applications of sequencing results are especially encouraged.

“Centrillion is a leader in deploying genomics research services to academic and clinical researchers”, said Wei Zhou, CEO of Centrillion, “With this program, we hope to encourage more researchers to apply advanced genomic technologies to advance their research goals.”

Proposals will be reviewed by a Centrillion-appointed committee consisting of Ph.D. level scientists with significant next generation sequencing and genomics technical application experience.

The program is open to all researchers in the USA. The submission deadline is May 17, 2013. Full details may be found on the Centrillion web site: http://www.centrillionbio.com

About Centrillion Biosciences Inc.
Centrillion Biosciences is a leading genomic and bioinformatics solution provider. Our genomic technology dramatically improves sequencing performance and is compatible with leading genomic technology platforms. With the highest customer return and referral rate, our genomic and bioinformatics services utilize leading technologies and beyond to deliver the highest quality data in the fastest sample to result time. Our world class genomic technology development expertise enables our customers to succeed in the most challenging genomic research projects.

Media Contacts
Robert Feldman, Ph.D.
Vice President of Business Development
Centrillion Biosciences, Inc.
2438 Embarcadero Way
Palo Alto, CA 94303
(650) 318-6235
pr(at)centrillionbio(dot)com

Read the full story at http://www.prweb.com/releases/2013/4/prweb10668083.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
2. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
3. Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference
4. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
5. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
6. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
7. Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
8. Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
9. Neurocrine Biosciences to Present at the 14th Annual BIO CEO & Investor Conference
10. Ambit Biosciences to Present at Two Upcoming Investor Conferences
11. GeneLink Biosciences Completes Sale of GeneWize Life Sciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... Feb. 27, 2017 AcelRx Pharmaceuticals, Inc. ... the development and commercialization of innovative therapies for ... the U.S. Food and Drug Administration (FDA) has ... section 505(b)(2) for DSUVIA™ (formerly ARX-04) (sufentanil sublingual ... with moderate-to-severe acute pain in a medically supervised ...
(Date:2/27/2017)... Fluxion Biosciences announced today that Genetracer Biotech ... appointed as a Certified Service Provider for Fluxion,s IsoFlux ... used in Genetracer Biotech,s novel liquid biopsy workflows for ... with plans to move to other cancers as additional ... System to isolate, recover, and analyze CTCs (circulating tumor ...
(Date:2/26/2017)... ... ... Lowe is a well recognized television personality, so it seems natural he would host ... to the American public and important to society at large. An upcoming episode will ... world for a few years. , The climate and how we relate to it ...
(Date:2/24/2017)... SAN FRANCISCO, CA (PRWEB) , ... February 24, 2017 , ... ... awarding of a $224K grant from the National Institute of Mental Health (NIMH) for ... is based on Delpor’s PROZOR technology and is expected to deliver therapeutic ...
Breaking Biology Technology:
(Date:2/14/2017)... Feb. 14, 2017  Wake Forest Baptist Medical Center ... new chief executive officer (CEO). Freischlag joins the medical ... D. McConnell , M.D., who last year announced that ... Medical Center, after leading it since 2008.   ... of Wake Forest Baptist,s academic health system, which includes ...
(Date:2/13/2017)... Feb. 13, 2017 Former 9/11 Commission border ... Committee, Janice Kephart of Identity Strategy Partners, ... Donald Trump,s "Executive Order: Protecting the Nation From ... 2017):  "As President Trump,s ,Travel Ban, Executive ... now essentially banned the travel ban, it is important ...
(Date:2/9/2017)... The biomass boiler market report by Transparency Market Research ... in terms of revenue (US$ Mn) based on the ... boilers has been segmented on the basis of feedstock ... based on feedstock type, has been segmented into woody ... urban residues, and others. On the basis of product ...
Breaking Biology News(10 mins):